HUTCHMED (China) Limited develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases through a China-based commercial organization and a global clinical pipeline. News for HCM centers on marketed oncology products such as FRUZAQLA and ELUNATE for fruquintinib, ORPATHYS for savolitinib, China regulatory actions, and partner-driven commercialization outside China.
Recurring updates also cover pipeline compounds including sovleplenib, HMPL-760 and HMPL-A580, clinical data presented at oncology meetings, and the company’s Antibody-Targeted Therapy Conjugate platform. Corporate items include annual results, product-license updates such as TAZVERIK in China, board and committee changes, and disclosures tied to HUTCHMED’s Nasdaq, AIM and HKEX listings and ADR structure.
Hutchison China MediTech Limited (Nasdaq/AIM: HCM) announced that CEO Mr. Christian Hogg will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on May 14, 2020, at 9:40 a.m. EDT. The event will be streamed live and can be accessed via the company's website. Following this conference, Chi-Med's senior management will hold one-on-one meetings at several upcoming events, including the Citi Virtual Pan-Asia Regional Investor Conference and Jefferies Global Healthcare Conference. Chi-Med aims to advance its pipeline of cancer therapies.